Gapping up
In reaction to strong earnings/guidance:
- YEXT +11.9%, CVET +10.8%, CNC +9.1% (updates guidance to include WellCare acquisition), FOXF +8.5%, AMBA +6.5%, HIIQ +6.4% (also plans to change name and ticker), BNFT +6.4%, ANF +6%, OSPN +4.5%, VEEV +3.9%, CPB +3.5%, GE +3% (reaffirms FY20 guidance) CNR +1.2%
Other news:
- NCNA +12.1% (EMA COMP has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with biliary tract cancer)
- KPTI +4.6% (prices offering of 6.25 mln shares of common stock at $24.00 per share)
- AMAG +4.6% (announces changes to its medical development organization; effective March 31, 2020, Julie Krop, Executive Vice President and Chief Medical Officer, will be leaving the Company)
- OGI +4.2% (announce that effective today Paolo De Luca, the Company's current CFO has been appointed Chief Strategy Officer and Derrick West, currently on the Company's Board of Directors, is joining the Company as its CFO)
- LMNX +2.9% (updates on the company's plans, progress, and capabilities in assisting laboratories to detect and diagnose cases of' COVID-19)
- EHTH +2.6% (prices 1.8 mln shares of common stock at $115.00 per share)
- ACAD +2.4% (announces that the FDA granted Rare Pediatric Disease designation to trofinetide for the treatment of Rett syndrome)
- BMY +2.3% (Bristol-Myers and Voluntis announce collaboration agreement to develop digital therapeutics for oncology)
- T +1.6% (recaps shareholder updates from conference; enters $4 bln ASR agreement)
- PTEN +1.5% (Feb drilling update)
- MKTX +1.3% (announces monthly trading volume for February of $592.1 bln)
- EXAS +1.3% (completes acquisitions of Paradigm Diagnostics and Viomics)
Analyst comments:
- FATE +8.5% (initiated with an Overweight at Barclays)
- CRON +4.5% (upgraded to Buy from Neutral at MKM Partners)
- AA +3.2% (upgraded to Neutral from Underperform at BofA/Merrill)
- CMG +2.8% (upgraded to Overweight from Equal Weight at Wells Fargo)
- ANET +2.6% (upgraded to Neutral from Underweight at JP Morgan)
- HD +2.6% (upgraded to Buy from Neutral at Nomura)
- AGNC +2.6% (upgraded to Outperform from Neutral at Wedbush)
- PFPT +2.4% (upgraded to Strong Buy at First Analysis Sec)
- WM +2.4% (upgraded to Buy from Neutral at UBS)
- TGT +2.1% (added to Conviction Buy List at Goldman)
- MS +2% (upgraded to Buy from Neutral at Citigroup)
- ORCL +1.6% (upgraded to Buy from Hold at Societe Generale)